Forest Laboratories announced its plan to discontinue the sale of Namenda (memantine HCl) 5mg and 10mg tablets on August 15, 2014. The discontinuation is not a result of any safety or efficacy issues.

Namenda is an NMDA receptor antagonist approved for the treatment of moderate-to-severe dementia of the Alzheimer’s type.

Forest is working to communicate with healthcare providers, pharmacists, patients, and caregivers about the discontinuation of Namenda. Namenda oral solution and Namenda XR extended-release capsules will continue to be available.

RELATED: Neurologic Disorders Resource Center

Prescribers are urged to transition patients to Namenda XR as soon as possible to maintain treatment continuity. As stated in the prescribing information, patients can be switched from Namenda to Namenda XR the very next day without titration. It is recommended that a patient who is on a regimen of 10mg twice daily of Namenda tablets be switched to Namenda XR 28mg once-daily capsules the day following the last dose of a 10mg Namenda tablet.

For more information call (844) 873-2823 or visit